Inventor · disambiguated record
Takuya Matsuo
Also filed as: MATSUO TAKUYA
4 granted patents·7 pending applications·1 citations·filing 2005–2024
55Inventor score
Top patents by PatentIndex Score
11 records- 0165US8008292B2Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activityJAPAN TOBACCO INC·Filed 2005·Granted Aug 30, 2011·1 cites·6 claims
- 0264US2025082609A1Heterocyclic sulfonamide derivatives and pharmaceutical uses thereofMETRION BIOSCIENCES LTD·Filed 2024·Application pending·0 cites
- 0359US2010022523A13-aminobenzamide compounds and vanilloid receptor subtype 1 (vr1) inhibitorsJAPAN TOBACCO INC·Filed 2009·Application pending·0 cites
- 0452US12128028B2Heterocyclic sulfonamide derivatives and pharmaceutical uses thereofMETRION BIOSCIENCES LTD·Filed 2019·Granted Oct 29, 2024·0 cites·23 claims
- 0550US2006035939A13-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activityJAPAN TOBACCO INC·Filed 2005·Application pending·0 cites
- 0645US10981877B2Production method for pyrazole-amide compoundJAPAN TOBACCO INC·Filed 2017·Granted Apr 20, 2021·0 cites·13 claims
- 0745US2012115827A13-aminobenzamide compounds and vanilloid receptor subtype 1 (vr1) inhibitorsKOGA YOSHIHISA·Filed 2011·Application pending·0 cites
- 0842US2015025120A1Pyrazole-alcohol compounds and pharmaceutical use thereofJAPAN TOBACCO INC·Filed 2014·Application pending·0 cites
- 0940US2015018403A1Fluorene-amide compounds and pharmaceutical use thereofJAPAN TOBACCO INC·Filed 2014·Application pending·0 cites
- 1039US2016137639A1Triazole-isoxazole compound and medical use thereofJAPAN TOBACCO INC·Filed 2013·Application pending·0 cites
- 1125US8765739B2Azetidine compound and pharmaceutical use thereofIKEGASHIRA KAZUTAKA·Filed 2010·Granted Jul 1, 2014·0 cites·10 claims
Join the waitlist — get patent alerts
Get an alert when Takuya Matsuo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →